Incyte's Jakafi Fails to Provide RELIEF in Polycythemia Vera - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 5:30PM CDT
Incyte (INCY) announced disappointing top-line results from the RELIEF study on Jakafi in the PV indication.
Alexion Pharmaceuticals Q2 Earnings In Line; Revises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 2:45PM CDT
Alexion (ALXN) reported in line earnings in the second quarter.
Actelion Beats on Q2 Earnings and Sales, Revises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 1:50PM CDT
Actelion LTD. (ALIOF) reported second-quarter earnings of $2.83 per American Depository Receipt (ADR), up 203.77% from the prior-year earnings of 93 cents per ADR, beating the Zacks Consensus Estimate of $1.37 per share.
Gilead Crushes Q2 Earnings Estimates as Sovaldi Sales Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:50AM CDT
Gilead (GILD) blew away estimates on strong Sovaldi sales.
Amicus Therapeutics (FOLD) Jumps: Stock Rises 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:39AM CDT
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as its shares rose over 7% on the day.
The Medicines Co.'s (MDCO) Q2 Earnings Decline Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:20AM CDT
The Medicines Co. (MDCO) has an important regulatory event coming up with the FDA expected to respond on the approval status of Orbactiv by Aug 6.
Medicines (MDCO) is Oversold: Can It Recover? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:01AM CDT
Medicines (MDCO) is Oversold: Can It Recover?
Biogen Idec (BIIB) Soars: Stock Adds 11.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 7:51AM CDT
Biogen Idec Inc. (BIIB) was a big mover last session, as its shares rose over 11% on the day.
Avanir to Conduct Phase II Study on AVP-786 for Depression - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 23, 4:50PM CDT
Avanir Pharmaceuticals, Inc.'s (AVNR) AVP-786 has been accepted by the FDA for a phase II study for the adjunctive treatment of major depressive disorder (MDD).
Biogen's Q2 Earnings Surpass Expectations, Tecfidera Shines - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 23, 12:20PM CDT
Biogen (BIIB) upped its earnings and revenue guidance significantly on the strong performance of Tecfidera and the AIFA agreement.
Cubist Misses Q2 Earnings Estimates on Weak Cubicin Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 23, 12:10PM CDT
Cubist's (CBST) second quarter earnings were short of the Zacks Consensus Estimate.
The Medicines Company Reports Second Quarter and First Half 2014 Results
Business Wire - Wed Jul 23, 6:00AM CDT
--Company Reports Progress of Four Regulatory Applications for US and Europe
Amgen's AMG 416 Succeeds in Phase III, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 12:23PM CDT
Amgen Inc. (AMGN) announced that AMG 416 (formerly known as velcalcetide) has met the primary as well as secondary endpoints in a phase III study.
3 Stocks With Jaw-Dropping Growth Potential
George Budwell, The Motley Fool - Motley Fool - Fri Jul 18, 4:03PM CDT
The biopharma industry has exploded with new public companies over the last two years. As a result, it's become all too easy to miss promising companies that offer stellar growth prospects going forward. MiMedx , The Medicines Company , and ...
Bristol-Myers/Pfizer Commence Phase IV Study on Eliquis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 3:45PM CDT
Bristol-Myers (BMY) and Pfizer (PFE) Began enrolling patients in a study on Eliquis.
Lannett Shares Down on Subpoena Receipt from Connecticut AG - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 4:10PM CDT
Lannett Company (LCI) has received a subpeona from Connecticut AG.
Rigel Pharmaceuticals Starts Fostamatinib Late Stage Program - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 3:45PM CDT
Rigel Pharma (RIGL) initiated a phase III program on fostamatinib .
Hospira Upgraded to Strong Buy on Orchid Facility Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 4:00PM CDT
On Jul 12, Zacks Investment Research upgraded Hospira Inc. (HSP) to a Zacks #1 Rank (Strong Buy).
Sunesis' Pediatric Plan Accepted in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 5:45PM CDT
Sunesis Pharmaceuticals, Inc.'s (SNSS) Pediatric Investigation Plan for Qinprezo was accepted by the EMA???s Pediatric Committee for AML.
Cytokinetics Up on Positive Tirasemtiv Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 4:00PM CDT
Cytokinetics Incorporated's (CYTK) shares jumped over 7% on Jul 11 after it announced that additional results from the BENEFIT-ALS study.